Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mednax

Share:
Related MD
Mednax's Unit MedData To Buy Duet Health For Undisclosed Terms
Benzinga's Top Downgrades

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mednax (NYSE: MD), and raised its price target from $81.00 to $88.00.

Jefferies noted, “MD is one of our top picks given our belief that the company's push to aggressively expand its anesthesiology business (which we expect mgmt to highlight at today's analyst day) will drive robust growth over the next several years that is not yet adequately reflected in the stock's valuation. Our positive bias is also driven by MD's highly defensive (i.e., benign) reimbursement outlook. Reiterate Buy/PT to $88.”

Mednax closed on Tuesday at $75.29.

Latest Ratings for MD

DateFirmActionFromTo
Mar 2016Stifel NicolausMaintainsBuy
Mar 2016SusquehannaDowngradesPositiveNeutral
Oct 2015SunTrust Robinson HumphreyMaintainsNeutral

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MD)

View Comments and Join the Discussion!